Prot# ACF4325g: An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics, and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination with Rituximab in Patients with CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodg

Project: Research project

Project Details

StatusFinished
Effective start/end date8/4/088/4/11

Funding

  • Genentech, Inc. (ACF4325g)